Is Zhengda Tianqing’s Pomalidomide included in the medical insurance?

Chia Tai Tianqing is a domestic pharmaceutical company. The domestic drug Pomalidomide produced by Zhengda Tianqing has been launched in China and has entered the scope of Class B medical insurance, which is suitable for people who have received at least two treatments in the past. (including lenalidomide and a proteasome inhibitor), and for adult patients with multiple myeloma whose disease has progressed during the last treatment or within 60 days after the end of treatment, the drug ingredients are basically the same as those of the original drug, but there are differences in specifications and prices.

Pomalidomide is an immunomodulator that binds to its molecular targetcereblon (a component of CRL 4 E3 ubiquitin ligase) and degrades the transcription factors Icarus and Ioros, exerting effective and direct tumoricidal and immunostimulatory effects. The antitumor and immunostimulatory properties of pomalidomide differ from those of lenalidomide; pomalidomide is also active in lenalidomide-resistant myeloma cell lines and animal models, and has demonstrated efficacy in lenalidomide-refractory patients in clinical trials.

Domestic pomalidomide may cost around 4,000 RMB per box, while the Turkish version sold overseas may cost around 15,000 RMB per box (the price may fluctuate due to exchange rates), which is relatively expensive. There are also cheaper generic drugs produced in other countries overseas. The price of each box produced by a Lao pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to the exchange rate). The ingredients of foreign generic drugs, domestically produced drugs and foreign original drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.